Structure–Activity Studies on Splitomicin Derivatives as Sirtuin Inhibitors and Computational Prediction of Binding Mode
- 13 February 2008
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (5), 1203-1213
- https://doi.org/10.1021/jm700972e
Abstract
NAD+-dependent histone deacetylases (sirtuins) are enzymes that cleave acetyl groups from lysines in histones and other proteins. Potent selective sirtuin inhibitors are interesting tools for the investigation of the biological functions of those enzymes and may be future drugs for the treatment of cancer. Splitomicin was among the first two inhibitors that were discovered for yeast sirtuins but showed rather weak inhibition on human enzymes. We present detailed structure–activity relationships on splitomicin derivatives and their inhibition of recombinant Sirt2. To rationalize our experimental results, ligand docking followed by molecular mechanics Poisson–Boltzmann/surface area (MM-PBSA) calculations were carried out. These analyses suggested a molecular basis for the interaction of the beta-phenylsplitomicins with human Sirt2. Protein-based virtual screening resulted in the identification of a novel Sirt2 inhibitor chemotype. Selected inhibitors showed antiproliferative properties and tubulin hyperacetylation in MCF7 breast cancer cells and are promising candidates for further optimization as potential anticancer drugs.Keywords
This publication has 53 references indexed in Scilit:
- Linking SIRT2 to Parkinson’s DiseaseACS Chemical Biology, 2007
- Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's DiseaseScience, 2007
- Chromatin Modifications as Targets for New Anticancer DrugsArchiv der Pharmazie, 2005
- SIRT1 Regulates HIV Transcription via Tat DeacetylationPLoS Biology, 2005
- Sirtuins: Sir2-related NAD-dependent protein deacetylasesGenome Biology, 2004
- Acetylation inactivates the transcriptional repressor BCL6Nature Genetics, 2002
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- Deacetylase EnzymesCell Chemical Biology, 2002
- hSIR2SIRT1 Functions as an NAD-Dependent p53 DeacetylaseCell, 2001
- Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylaseNature, 2000